Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra

Overview

Journal J Neurodegener Dis

Date 2015 Aug 29

PMID 26316987

Citations 6

Authors

A Harkavyi

N Rampersaud

P S Whitton

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) activation by exendin-4 (EX-4) is effective in preclinical models of Parkinson's disease (PD) and appears to promote neurogenesis even in severely lesioned rats. In the present study, we determined the effects of EX-4 on cellular BrdU incorporation in the rat subventricular zone (SVZ) and substantia nigra (SN). We also determined the specificity of this effect with the GLP-1R antagonist EX-(9-39) as well as the potential role of dopamine (DA) D3 receptors. Rats were administered 6-OHDA and 1 week later given EX-4 alone, with EX-(9-39) or nafadotride (D3 antagonist) and BrdU. Seven days later, rats were challenged with apomorphine to evaluate circling. Extracellular DA was measured using striatal microdialysis and subsequently tissue DA measured. Tyrosine hydroxylase and BrdU were verified using immunohistochemistry. Apomorphine circling was reversed by EX-4 in lesioned rats, an effect reduced by EX-4, while both EX-(9-39) and NAF attenuated this. 6-OHDA decreased extracellular and tissue DA, both reversed by EX-4 but again attenuated by EX-(9-39) or NAF. Analysis of BrdU+ cells in the SVZ revealed increases in 6-OHDA-treated rats which were reversed by EX-4 and antagonised by either EX-(9-39) or NAF, while in the SN the opposite profile was seen.

Citing Articles

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.

Mehdi S, Pusapati S, Anwar M, Lohana D, Kumar P, Nandula S Front Immunol. 2023; 14:1148209.

PMID: 37266425 PMC: 10230051. DOI: 10.3389/fimmu.2023.1148209.

L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.

Elabi O, Davies J, Lane E Int J Mol Sci. 2021; 22(22).

PMID: 34830228 PMC: 8618072. DOI: 10.3390/ijms222212346.

Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.

Wang V, Kuo T, Yi-Kung Huang E, Ma K, Chou Y, Fu Z ACS Pharmacol Transl Sci. 2021; 4(2):858-869.

PMID: 33860208 PMC: 8033754. DOI: 10.1021/acsptsci.1c00013.

Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Glotfelty E, Delgado T, Tovar-y-Romo L, Luo Y, Hoffer B, Olson L ACS Pharmacol Transl Sci. 2019; 2(2):66-91.

PMID: 31396586 PMC: 6687335. DOI: 10.1021/acsptsci.9b00003.

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Chen S, Yu S, Li Y, Lecca D, Glotfelty E, Kim H Sci Rep. 2018; 8(1):10722.

PMID: 30013201 PMC: 6048117. DOI: 10.1038/s41598-018-28449-z.

References

Park S, Hong S, Sung S . Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats. Life Sci. 2008; 82(9-10):503-11. DOI: 10.1016/j.lfs.2007.12.018. View

Zhao C, Deng W, Gage F . Mechanisms and functional implications of adult neurogenesis. Cell. 2008; 132(4):645-60. DOI: 10.1016/j.cell.2008.01.033. View

Kim Y, Wang W, Comte I, Pastrana E, Tran P, Brown J . Dopamine stimulation of postnatal murine subventricular zone neurogenesis via the D3 receptor. J Neurochem. 2010; 114(3):750-60. PMC: 2913229. DOI: 10.1111/j.1471-4159.2010.06799.x. View

Liu B, Gao E, Zeng X, Ji M, Cai Q, Lu Q . Proliferation of neural precursors in the subventricular zone after chemical lesions of the nigrostriatal pathway in rat brain. Brain Res. 2006; 1106(1):30-39. DOI: 10.1016/j.brainres.2006.05.111. View

Li Y, Perry T, Kindy M, Harvey B, Tweedie D, Holloway H . GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009; 106(4):1285-90. PMC: 2633544. DOI: 10.1073/pnas.0806720106. View

Freundlieb N, Francois C, Tande D, Oertel W, Hirsch E, Hoglinger G . Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci. 2006; 26(8):2321-5. PMC: 6674815. DOI: 10.1523/JNEUROSCI.4859-05.2006. View

Coronas V, Bantubungi K, Fombonne J, Krantic S, Schiffmann S, Roger M . Dopamine D3 receptor stimulation promotes the proliferation of cells derived from the post-natal subventricular zone. J Neurochem. 2004; 91(6):1292-301. DOI: 10.1111/j.1471-4159.2004.02823.x. View

Anderson D, Neavin T, Smith J, Schneider J . Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res. 2001; 905(1-2):44-53. DOI: 10.1016/s0006-8993(01)02466-0. View

Van Kampen J, Hagg T, Robertson H . Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur J Neurosci. 2004; 19(9):2377-87. DOI: 10.1111/j.0953-816X.2004.03342.x. View

10.

Jin S, Han V, Simmons J, Towle A, Lauder J, Lund P . Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol. 1988; 271(4):519-32. DOI: 10.1002/cne.902710405. View

11.

Kastin A, Akerstrom V . Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003; 27(3):313-8. DOI: 10.1038/sj.ijo.0802206. View

12.

Vu T, Ling Z, Ma S, Robie H, Tong C, Chen E . Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm (Vienna). 2000; 107(2):159-76. DOI: 10.1007/s007020050014. View

13.

Satoh F, Beak S, Small C, Falzon M, Ghatei M, Bloom S . Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology. 2000; 141(4):1301-9. DOI: 10.1210/endo.141.4.7420. View

14.

Hoglinger G, Rizk P, Muriel M, Duyckaerts C, Oertel W, Caille I . Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci. 2004; 7(7):726-35. DOI: 10.1038/nn1265. View

15.

Joyce J, Presgraves S, Renish L, Borwege S, Osredkar T, Hagner D . Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp Neurol. 2003; 184(1):393-407. DOI: 10.1016/s0014-4886(03)00353-4. View

16.

Kim S, Moon M, Park S . Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol. 2009; 202(3):431-9. DOI: 10.1677/JOE-09-0132. View

17.

Aponso P, Faull R, Connor B . Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Neuroscience. 2008; 151(4):1142-53. DOI: 10.1016/j.neuroscience.2007.11.036. View

18.

Boulougouris V, Castane A, Robbins T . Dopamine D2/D3 receptor agonist quinpirole impairs spatial reversal learning in rats: investigation of D3 receptor involvement in persistent behavior. Psychopharmacology (Berl). 2008; 202(4):611-20. DOI: 10.1007/s00213-008-1341-2. View

19.

Ramirez A, Wong S, Menniti F . Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur J Pharmacol. 2003; 475(1-3):29-35. DOI: 10.1016/s0014-2999(03)02087-9. View

20.

Frielingsdorf H, Schwarz K, Brundin P, Mohapel P . No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A. 2004; 101(27):10177-82. PMC: 454184. DOI: 10.1073/pnas.0401229101. View